Efficacy and Safety Findings from the COMMAND Study
A hematologist-oncologist discusses the efficacy and safety findings from the COMMANDS trial and how they inform treatment selection.
EP: 1.Approach to 1L Therapy Selection in Lower-Risk MDS
EP: 2.Efficacy and Safety Findings from the COMMAND Study
EP: 3.Assessing QoL in MDS Patients
EP: 4.Clinical Benefit of Luspatercept Dose Titration: Real-World Evidence
EP: 5.Key Takeaways and Unmet Needs in Lower-Risk MDS Anemia Management
Case: Frontline Use of Erythroid Maturating Agent (EMA): Luspatercept
Clinical Presentation:
70-year-old man diagnosed 6 months ago with LR-MDS with multilineage dysplasia - moderate anemia (Hb 11.2) and thrombocytosis (PLT 500,000 μl)
- SF3B1 mutation positive
- Non-del(5q)
- No family history of cancer or significant genotoxic agent exposure
- IPSS-R: Low
Current Visit Clinical Workup and Diagnosis:
- Serum EPO - 250m U/L, Ring sideroblast (RS) negative
- Hgb: 9.2 g/dL.
- WBC and ANC: WNL
- PLT: 450,000 μl
He complains of increasing fatigue over the past 1-2 months. He normally plays 2-3 rounds of golf a week. Lately he has only been playing a full round once a week and maybe 9 holes on another day.
Initial Treatment(s):
- The patient was started on luspatercept at the starting dose [1.0 mg/kg] as 1L therapy.
- After 24 weeks, the patient has not received any transfusion and his Hgb is now 10.7 g/dL.
Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS
September 5th 2024During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.
Read More
Luspatercept in MDS Promotes Transfusion Independence and Anemia Response
August 21st 2024During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
Read More
